FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028124348> ?p ?o ?g. }

• W2028124348 endingPage "S50" @default.
• W2028124348 startingPage "S50" @default.
• W2028124348 abstract "Purpose/Objective: Pigmented villonodular synovitis (PVNS) is a rare proliferative process originating from synovial membranes. Usually benign, it may be destructive, resulting in major symptoms and loss of function leading to amputation rarely. There is a paucity of outcome data following radiotherapy in high risk cases. Our purpose was to update a prior experience with extended follow-up and almost three times greater accrual of cases at high risk for recurrence with functional loss including instances where amputation was the sole alternative for symptomatic disease.Materials/Methods: The records of all patients (41 cases) who received radiotherapy for PVNS between 1972 and 2003 were reviewed retrospectively and, since 1986, prospectively. Eligibility included at least one year of follow-up following radiotherapy. Local control was defined as absence of clinical or imaging evidence of disease following treatment in either patients without overt disease at the time of radiotherapy, or in patients with stable disease on serial cross-sectional imaging of gross disease for at least one year following treatment.Results: All cases had pathologic confirmation of diagnosis at our center. 18 had primary and 23 recurrent disease (with a mean of 2 prior surgical procedures). 36 had origin from a joint (most commonly the knee in 37%) and 5 arose in periarticular tendon sheath. All but 1 had both intra- and extraarticular disease and, without exception, the poorer prognosis diffuse subtype of the disease. The majority had one or more additional risk factors including skin, bone, tendon, neurovascular, or muscle group extension and 17 of these lesion exceeded 10 cm in maximum dimension. 21 had gross residual disease at the time of radiotherapy. The mean radiotherapy dose was 38 Gy (range 28 Gy to 50 Gy), the majority receiving 35 Gy in 14 fractions. One patient had the malignant variant of PVNS and is the only patient with clear resection margins consistent with oncologic principles for malignant sarcomas. With a mean follow-up time of 77 months (range 13–337 months), only one patient has shown active disease by the criteria described. Two additional cases (both tendon sheath lesions of the wrist/hand) underwent subsequent biopsies of a palpable asymptomatic stable lesion (<1 cm in size). In one this took place 9 years following radiotherapy and he remained without treatment or progression 17 years later; the second had a biopsy 16 years following treatment, had no additional therapy and was well without progression 3 years later. No patient required amputation, and none had evidence of serious radiotherapy complications. Only one patient has developed a second malignancy, specifically a brain tumor but the site of PVNS was the ankle.Conclusions: Moderate dose radiotherapy is a very effective treatment in PVNS and permits local control and avoidance of amputation in very advanced and typically recurrent cases. When treatment is indicated we currently recommend gross total removal of PVNS followed by moderate dose radiotherapy for residual disease where salvage of subsequent recurrence may compromise function. Alternatively control of gross disease can also be expected following radiotherapy. Purpose/Objective: Pigmented villonodular synovitis (PVNS) is a rare proliferative process originating from synovial membranes. Usually benign, it may be destructive, resulting in major symptoms and loss of function leading to amputation rarely. There is a paucity of outcome data following radiotherapy in high risk cases. Our purpose was to update a prior experience with extended follow-up and almost three times greater accrual of cases at high risk for recurrence with functional loss including instances where amputation was the sole alternative for symptomatic disease. Materials/Methods: The records of all patients (41 cases) who received radiotherapy for PVNS between 1972 and 2003 were reviewed retrospectively and, since 1986, prospectively. Eligibility included at least one year of follow-up following radiotherapy. Local control was defined as absence of clinical or imaging evidence of disease following treatment in either patients without overt disease at the time of radiotherapy, or in patients with stable disease on serial cross-sectional imaging of gross disease for at least one year following treatment. Results: All cases had pathologic confirmation of diagnosis at our center. 18 had primary and 23 recurrent disease (with a mean of 2 prior surgical procedures). 36 had origin from a joint (most commonly the knee in 37%) and 5 arose in periarticular tendon sheath. All but 1 had both intra- and extraarticular disease and, without exception, the poorer prognosis diffuse subtype of the disease. The majority had one or more additional risk factors including skin, bone, tendon, neurovascular, or muscle group extension and 17 of these lesion exceeded 10 cm in maximum dimension. 21 had gross residual disease at the time of radiotherapy. The mean radiotherapy dose was 38 Gy (range 28 Gy to 50 Gy), the majority receiving 35 Gy in 14 fractions. One patient had the malignant variant of PVNS and is the only patient with clear resection margins consistent with oncologic principles for malignant sarcomas. With a mean follow-up time of 77 months (range 13–337 months), only one patient has shown active disease by the criteria described. Two additional cases (both tendon sheath lesions of the wrist/hand) underwent subsequent biopsies of a palpable asymptomatic stable lesion (<1 cm in size). In one this took place 9 years following radiotherapy and he remained without treatment or progression 17 years later; the second had a biopsy 16 years following treatment, had no additional therapy and was well without progression 3 years later. No patient required amputation, and none had evidence of serious radiotherapy complications. Only one patient has developed a second malignancy, specifically a brain tumor but the site of PVNS was the ankle. Conclusions: Moderate dose radiotherapy is a very effective treatment in PVNS and permits local control and avoidance of amputation in very advanced and typically recurrent cases. When treatment is indicated we currently recommend gross total removal of PVNS followed by moderate dose radiotherapy for residual disease where salvage of subsequent recurrence may compromise function. Alternatively control of gross disease can also be expected following radiotherapy." @default.
• W2028124348 created "2016-06-24" @default.
• W2028124348 creator A5000970066 @default.
• W2028124348 creator A5002302013 @default.
• W2028124348 creator A5003636337 @default.
• W2028124348 creator A5005156213 @default.
• W2028124348 creator A5017899349 @default.
• W2028124348 creator A5018765602 @default.
• W2028124348 creator A5028513610 @default.
• W2028124348 creator A5033691574 @default.
• W2028124348 creator A5037725319 @default.
• W2028124348 creator A5060444850 @default.
• W2028124348 date "2005-10-01" @default.
• W2028124348 modified "2023-10-16" @default.
• W2028124348 title "Sustained Remission Following Radiation Treatment for High-Risk Pigmented Villonodular Synovitis" @default.
• W2028124348 doi "https://doi.org/10.1016/j.ijrobp.2005.07.088" @default.
• W2028124348 hasPublicationYear "2005" @default.
• W2028124348 type Work @default.
• W2028124348 sameAs 2028124348 @default.
• W2028124348 citedByCount "8" @default.
• W2028124348 countsByYear W20281243482012 @default.
• W2028124348 countsByYear W20281243482023 @default.
• W2028124348 crossrefType "journal-article" @default.
• W2028124348 hasAuthorship W2028124348A5000970066 @default.
• W2028124348 hasAuthorship W2028124348A5002302013 @default.
• W2028124348 hasAuthorship W2028124348A5003636337 @default.
• W2028124348 hasAuthorship W2028124348A5005156213 @default.
• W2028124348 hasAuthorship W2028124348A5017899349 @default.
• W2028124348 hasAuthorship W2028124348A5018765602 @default.
• W2028124348 hasAuthorship W2028124348A5028513610 @default.
• W2028124348 hasAuthorship W2028124348A5033691574 @default.
• W2028124348 hasAuthorship W2028124348A5037725319 @default.
• W2028124348 hasAuthorship W2028124348A5060444850 @default.
• W2028124348 hasBestOaLocation W20281243481 @default.
• W2028124348 hasConcept C105572291 @default.
• W2028124348 hasConcept C126322002 @default.
• W2028124348 hasConcept C126838900 @default.
• W2028124348 hasConcept C141071460 @default.
• W2028124348 hasConcept C2775882047 @default.
• W2028124348 hasConcept C2776204877 @default.
• W2028124348 hasConcept C2776791232 @default.
• W2028124348 hasConcept C2777077863 @default.
• W2028124348 hasConcept C2777575956 @default.
• W2028124348 hasConcept C2779134260 @default.
• W2028124348 hasConcept C2779244835 @default.
• W2028124348 hasConcept C509974204 @default.
• W2028124348 hasConcept C71924100 @default.
• W2028124348 hasConceptScore W2028124348C105572291 @default.
• W2028124348 hasConceptScore W2028124348C126322002 @default.
• W2028124348 hasConceptScore W2028124348C126838900 @default.
• W2028124348 hasConceptScore W2028124348C141071460 @default.
• W2028124348 hasConceptScore W2028124348C2775882047 @default.
• W2028124348 hasConceptScore W2028124348C2776204877 @default.
• W2028124348 hasConceptScore W2028124348C2776791232 @default.
• W2028124348 hasConceptScore W2028124348C2777077863 @default.
• W2028124348 hasConceptScore W2028124348C2777575956 @default.
• W2028124348 hasConceptScore W2028124348C2779134260 @default.
• W2028124348 hasConceptScore W2028124348C2779244835 @default.
• W2028124348 hasConceptScore W2028124348C509974204 @default.
• W2028124348 hasConceptScore W2028124348C71924100 @default.
• W2028124348 hasLocation W20281243481 @default.
• W2028124348 hasOpenAccess W2028124348 @default.
• W2028124348 hasPrimaryLocation W20281243481 @default.
• W2028124348 hasRelatedWork W1908725238 @default.
• W2028124348 hasRelatedWork W2043722464 @default.
• W2028124348 hasRelatedWork W2060029045 @default.
• W2028124348 hasRelatedWork W2120633854 @default.
• W2028124348 hasRelatedWork W2347870403 @default.
• W2028124348 hasRelatedWork W2384949202 @default.
• W2028124348 hasRelatedWork W2416487075 @default.
• W2028124348 hasRelatedWork W2430148460 @default.
• W2028124348 hasRelatedWork W2471293390 @default.
• W2028124348 hasRelatedWork W2550972123 @default.
• W2028124348 hasVolume "63" @default.
• W2028124348 isParatext "false" @default.
• W2028124348 isRetracted "false" @default.
• W2028124348 magId "2028124348" @default.
• W2028124348 workType "article" @default.